Robert C. Goeltz's most recent trade in Arcus Biosciences Inc was a trade of 150,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on Jan. 23, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Arcus Biosciences Inc | Robert C. Goeltz | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 150,000 | 150,000 | - | - | Stock Option (right to buy) | |
| Arcus Biosciences Inc | Robert C. Goeltz | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 37,000 | 97,138 (0%) | 0% | 0 | Common Stock | |
| Arcus Biosciences Inc | Robert C. Goeltz | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 15.00 per share. | 31 Dec 2024 | 3,594 | 60,138 (0%) | 0% | 15 | 53,910 | Common Stock |
| Arcus Biosciences Inc | Robert C. Goeltz | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.08 per share. | 15 Dec 2024 | 10,099 | 63,732 (0%) | 0% | 16.1 | 162,392 | Common Stock |
| Arcus Biosciences Inc | Goeltz Robert C. | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 86,600 | 86,600 | - | - | Stock Option (right to buy) | |
| Arcus Biosciences Inc | Robert C. Goeltz | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 22,000 | 73,831 (0%) | 0% | 0 | Common Stock | |
| Arcus Biosciences Inc | Goeltz Robert C. | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 21,300 | 73,131 (0%) | 0% | 0 | Common Stock | |
| Arcus Biosciences Inc | Robert Goeltz C. | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 02 Jan 2024 | 2,004 | 51,831 (0%) | 0% | 20 | 40,080 | Common Stock |
| Arcus Biosciences Inc | Goeltz C. Robert | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 18.09 per share. | 18 Dec 2023 | 2,808 | 53,835 (0%) | 0% | 18.1 | 50,797 | Common Stock |
| Arcus Biosciences Inc | Robert C. Goeltz | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 17.74 per share. | 18 Dec 2023 | 2,749 | 56,643 (0%) | 0% | 17.7 | 48,767 | Common Stock |
| Arcus Biosciences Inc | Robert C. Goeltz | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 20.04 per share. | 07 Jun 2023 | 4,049 | 59,392 (0%) | 0% | 20.0 | 81,142 | Common Stock |
| Arcus Biosciences Inc | Robert C. Goeltz | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2023 | 138,200 | 138,200 | - | - | Stock Option (right to buy) | |
| Arcus Biosciences Inc | Robert C. Goeltz | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2023 | 34,000 | 63,441 (0%) | 0% | 0 | Common Stock | |
| Arcus Biosciences Inc | Robert C. Goeltz | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 30.66 per share. | 16 Dec 2022 | 2,066 | 11,953 (0%) | 0% | 30.7 | 63,344 | Common Stock |
| Arcus Biosciences Inc | Robert C. Goeltz | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 31.23 per share. | 16 Dec 2022 | 387 | 11,566 (0%) | 0% | 31.2 | 12,086 | Common Stock |
| Arcus Biosciences Inc | Robert C. Goeltz | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2022 | 62,500 | 62,500 | - | - | Stock Option (right to buy) | |
| Arcus Biosciences Inc | Robert C. Goeltz | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2022 | 15,500 | 22,519 (0%) | 0% | 0 | Common Stock | |
| Arcus Biosciences Inc | Robert C. Goeltz | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 39.59 per share. | 16 Dec 2021 | 354 | 7,771 (0%) | 0% | 39.6 | 14,015 | Common Stock |
| Arcus Biosciences Inc | Robert C. Goeltz | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 41.42 per share. | 16 Dec 2021 | 224 | 7,019 (0%) | 0% | 41.4 | 9,279 | Common Stock |
| Arcus Biosciences Inc | Robert C. Goeltz | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 40.57 per share. | 16 Dec 2021 | 171 | 7,243 (0%) | 0% | 40.6 | 6,938 | Common Stock |
| Arcus Biosciences Inc | Robert C. Goeltz | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 38.79 per share. | 16 Dec 2021 | 138 | 7,502 (0%) | 0% | 38.8 | 5,353 | Common Stock |
| Arcus Biosciences Inc | Robert C. Goeltz | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 40.46 per share. | 16 Dec 2021 | 131 | 7,640 (0%) | 0% | 40.5 | 5,300 | Common Stock |
| Arcus Biosciences Inc | Robert C. Goeltz | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 39.67 per share. | 16 Dec 2021 | 88 | 7,414 (0%) | 0% | 39.7 | 3,491 | Common Stock |
| Arcus Biosciences Inc | Robert C. Goeltz | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2021 | 75,000 | 75,000 | - | - | Stock Option (right to buy) | |
| Arcus Biosciences Inc | Robert C. Goeltz | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2021 | 12,500 | 17,500 (0%) | 0% | 0 | Common Stock | |
| Arcus Biosciences Inc | Robert C. Goeltz | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 21.57 per share. | 09 Sep 2020 | 5,000 | 5,000 (0%) | 0% | 21.6 | 107,849 | Common Stock |
| Arcus Biosciences Inc | Robert C. Goeltz | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Aug 2020 | 250,000 | 250,000 | - | - | Stock Option (right to buy) |